NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

MAZE

Maze Therapeutics Inc

Apr 24 • 02:32PM ET

8.44

Dollar change -1.11
Percentage change -11.67	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF VTWO IWO SCHA IWN IWC VTWG RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	48.42%	Shs Outstand	43.80M	Perf Week	3.12%
Market Cap	369.43M	Forward P/E	-	EPS next Y	-2.76	Insider Trans	0.00%	Shs Float	22.59M	Perf Month	-27.47%
Income	-	PEG	-	EPS next Q	-0.72	Inst Own	12.60%	Short Float	11.88%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-315.41%	Inst Trans	6.90%	Short Ratio	8.82	Perf Half Y	-
Book/sh	-7.11	P/B	-	EPS next Y	-2.49%	ROA	-	Short Interest	2.68M	Perf Year	-
Cash/sh	4.49	P/C	1.88	EPS next 5Y	-	ROE	-	52W Range	6.71 - 17.00	Perf YTD	-47.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-50.38%	Beta	-
Dividend TTM	-	Quick Ratio	9.76	Sales past 5Y	0.00%	Gross Margin	-	52W Low	25.71%	ATR (14)	1.19
Dividend Ex-Date	-	Current Ratio	9.76	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	41.01	Volatility	11.43% 12.65%
Employees	125	Debt/Eq	0.14	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	25.67
Option/Short	No / Yes	LT Debt/Eq	0.11	EPS Q/Q	-	Payout	-	Rel Volume	0.23	Prev Close	9.55
Sales Surprise	-	EPS Surprise	-993.66%	Sales Q/Q	-	Earnings	Mar 31 BMO	Avg Volume	304.49K	Price	8.44
SMA20	-7.52%	SMA50	-20.94%	SMA200	-23.83%	Trades		Volume	55,549	Change	-11.67%

Mar-31-25 07:30AM	Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights (GlobeNewswire)
Mar-26-25 05:02PM	Maze Therapeutics: Interesting Science But IPO-Related And Other Risks Exist (SeekingAlpha) -7.48%
Feb-25-25 04:11PM	Maze Therapeutics receives positive ratings following recent IPO (Investing.com) +10.69%
Feb-10-25 07:09AM	Maze Therapeutics doses first subject in Phase II AKD treatment trial (Clinical Trials Arena)
Feb-07-25 08:00AM	Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease (GlobeNewswire)
08:13PM	Loading…
Jan-30-25 08:13PM	Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs (Bloomberg)
07:30PM	Maze Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
02:57PM	Metsera, Maze secure combined $415 million in IPOs (BioPharma Dive)

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes Compass platform, which allows to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 28, 2019 and is headquartered in San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MAZE

Maze Therapeutics Inc

Upgrade your FINVIZ experience